{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.2","upperLimit":"6.6","value":"4.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Time to treatment failure is defined to be the time from registration to the date at which the patient is removed from treatment due to progression, adverse events, or refusal. The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"All Patients (Everolimus and Lenalidomide)"}],"paramType":"MEDIAN","populationDescription":"Fifty-five patients began study treatment and were eligible for response evaluation were pooled and included in this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Time to Treatment Failure for All Eligible Patients","type":"SECONDARY","unitOfMeasure":"months"}